ArticleImmunogenetics2025
Association between single-nucleotide polymorphism rs868875 of CLEC4M gene and clinical severity of COVID-19 in a Brazilian population.
Article in Immunogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
COVID-19, caused by the SARS-CoV-2 virus, has had a global impact, leading to high incidence and mortality rates worldwide. Host genetics significantly influence individual susceptibility to severe COVID-19. The C-type lectin domain family 4 member M (CLEC4M) gene plays an important role in SARS-CoV-2 infection and coagulation pathways. In this study, we genotyped and investigated the functional variant rs868875 of the CLEC4M gene in COVID-19 patients receiving anticoagulant therapy. This cross-sectional study included 485 patients, divided into moderate (n = 139) and critical/severe (n = 346) groups. Significant disparities in D-dimer levels were observed between patient groups (p < 0.0001), thus serving as a critical marker for stratification. Genetic analysis revealed significant associations between allele (p = 0.0170) and genotype (p = 0.0096) frequencies across the groups. Regarding genotypic models, an association was found in dominant (p = 0.0035) and overdominant (p = 0.004) models. Logistic regression confirmed that the presence of G allele (AG/GG) significantly impacts COVID-19 severity, independent of confounding variables (p = 0.017). Moreover, expression quantitative trait loci (eQTLs) analysis indicated that the GG genotype of rs868875 is associated with lower CLEC4M gene expression in lung and liver tissue, and STRING analysis revealed relevant biological interactions between CLEC4M and other genes in the inflammatory process, innate immunity, and vascular response. Overall, our findings suggest an association between the rs868875 polymorphism and severe clinical outcomes of COVID-19 in patients receiving anticoagulants. However, further validation studies are essential to corroborate these findings and elucidate the functional implications of this polymorphism. These efforts will contribute to a comprehensive understanding of the pathogenesis of COVID-19.
Indexed as
Identifiers
41062837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.